Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process
- Barrett's Dysplasia Cancer Task Force - BADCAT
- Barrett’s Dysplasia Cancer Task Force (BADCAT)
- Publication date:
- 24 April 2012
Esophageal adenocarcinoma (EA) is increasingly common among patients with Barrett's esophagus (BE). This guideline aims to provide consensus recommendations based on the medical literature that clinicians could use to manage patients with BE and low-grade dysplasia, high-grade dysplasia (HGD), or early-stage EA.